Comparative pathology of dog and human prostate cancer.

Autor: Ryman-Tubb T; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., Lothion-Roy JH; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., Metzler VM; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., Harris AE; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., Robinson BD; Department of Pathology, Weill Cornell Medicine, NY, New York, USA., Rizvanov AA; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.; Institute of Fundamental Medicine and Science, Kazan Federal University, Kazan, Tatarstan, Russia., Jeyapalan JN; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., James VH; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., England G; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., Rutland CS; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK., Persson JL; Department of Molecular Biology, Umeå Universitet, Umeå, Sweden.; Department of Biomedical Sciences, Malmö Universitet, Malmö, Sweden., Kenner L; Department of Experimental Pathology, Laboratory Animal Pathology Medical University Wien, Vienna, Austria., Rubin MA; Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland.; Department of BioMedical Research, University of Bern and Inselspital, Bern, Switzerland., Mongan NP; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.; Department of Pharmacology, Weill Cornell Medicine, New York, New York, USA., de Brot S; BioDiscovery Institute, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.; COMPATH, Institute of Animal Pathology, University of Bern, Bern, Switzerland.
Jazyk: angličtina
Zdroj: Veterinary medicine and science [Vet Med Sci] 2022 Jan; Vol. 8 (1), pp. 110-120. Date of Electronic Publication: 2021 Oct 10.
DOI: 10.1002/vms3.642
Abstrakt: Though relatively rare in dogs, prostate cancer (PCa) is the most common non-cutaneous cancer in men. Human and canine prostate glands share many functional, anatomical and physiological features. Due to these similarities, canine PCa has been proposed as a model for PCa in men. PCa is typically androgen-dependent at diagnosis in men and for this reason, androgen deprivation therapies (ADT) are important treatments for advanced PCa in men. In contrast, there is some evidence that PCa is diagnosed more commonly in castrate dogs, at which point, limited therapeutic options are available. In men, a major limitation of current ADT is that progression to a lethal and incurable form of PCa, termed castrate-resistant prostate cancer (CRPC), is common. There is, therefore, an urgent need for a better understanding of the mechanism of PCa initiation and progression to CRPC to enable the development of novel therapeutic approaches. This review focuses on the functional, physiological, endocrine and histopathological similarities and differences in the prostate gland of these species. In particular, we focus on common physiological roles for androgen signalling in the prostate of men and dogs, we review the short- and longer-term effects of castration on PCa incidence and progression in the dog and relate how this knowledge may be relevant to understanding the mechanisms of CRPC in men.
(© 2021 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje